Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

By sjmartinez • September 10, 2024

Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial. EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. PMID: 39252866; PMCID: PMC11381616.

Tags: Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, long COVID, Monoclonal antibodies, outpatient treatment, PASC, Post COVID conditions, Post-acute sequelae of SARS-CoV-2 infection, Publications

Heart failure and atrial fibrillation prediction from non-gated chest CT scans using AI-based cardiac chamber volumetry: an AI-CVD study within the multi-ethnic study of atherosclerosis (MESA)

Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Ghaffari Jolfayi A, Atlas T, Henschke CI, Yankelevitz DF,[...]

Editorial: The experimental models as a tool for studying therapeutic targets in COPD: lessons learned

Degobbi T Q S Lopes F, Vieira RP, Abbasi A. Editorial: The experimental models as a tool for studying therapeutic targets in COPD: lessons learned.[...]

Comparison of AI-enabled cardiac chambers volumetry based on non-gated chest CT scans with echocardiography: An AI-CVD study within the Multi-Ethnic Study of Atherosclerosis (MESA)

Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Ghaffari Jolfayi A, Atlas T, Henschke CI, Yankelevitz DF,[...]